MATWIN
Created in 2011
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
287 1,093 2,694Activities
Entity types
Location
229 Cr de l'Argonne, 33076 Bordeaux Cedex, France
Bordeaux
France
Employees
Scale: 2-10
Estimated: 7
SIREN
691152797Engaged corporates
71
19 62Added in Motherbase
5 years, 9 months ago
deeptech Value proposition
French Accelerator dedicated to innovation in oncology
MATWIN (Maturation & Accelerating Translation With INdustry) est un programme accélérateur pour développer la recherche translationnelle en cancérologie et faciliter le transfert des innovations vers les patients. Son objectif principal est d'accompagner des projets innovants (issus de laboratoires académiques ou portés par des startups) et présentant un fort potentiel de développement en favorisant des partenariats précoces. Le programme s’appuie sur un partenariat avec de grands laboratoires engagés en oncologie (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) et l’ensemble des acteurs soucieux de développer l’innovation dans le domaine (Cancéropôles, TTOs, pôles de compétitivité, etc.).
Depuis 2015, la société qui porte le programme est devenue filiale à 100% du groupe Unicancer.
Appel à candidatures MATWIN : https://matwin.fr/appel-a-projets-matwin/
MATWIN “Maturation & Accelerating Translation With Industry” is a French accelerator supporting translational innovation in oncology. The programme main objective is to select R&D innovative projects with high transfer potential and therapeutic/ diagnosis application in oncology and to support them in the development and closing of early-stage partnerships to accelerate innovation transfer from bench to the bedside.
This programme is supported by most of the largest companies working in oncology (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and representatives of the French innovation ecosystem (Cancéropôles, TTO, competitive clusters, etc.) Since 2015, MATWIN is a wholly-owned subsidiary from UNICANCER group
MATWIN Call for Applications (open to EU teams) : https://matwin.fr/en/matwins-call-for-application/
Valorisation, Transfert de technologie, Partenariat de recherche Oncologie, Maturation de la recherche, Recherche oncologie, Open Innovation, Partenariat public-privé, Innovation ouverte, Innovation Santé, Cancérologie, and OncologieOriginal language
French Accelerator dedicated to innovation in oncology
MATWIN (Maturation & Accelerating Translation With INdustry) est un programme accélérateur pour développer la recherche translationnelle en cancérologie et faciliter le transfert des innovations vers les patients. Son objectif principal est d'accompagner des projets innovants (issus de laboratoires académiques ou portés par des startups) et présentant un fort potentiel de développement en favorisant des partenariats précoces. Le programme s’appuie sur un partenariat avec de grands laboratoires engagés en oncologie (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) et l’ensemble des acteurs soucieux de développer l’innovation dans le domaine (Cancéropôles, TTOs, pôles de compétitivité, etc.).
Depuis 2015, la société qui porte le programme est devenue filiale à 100% du groupe Unicancer.
Appel à candidatures MATWIN : https://matwin.fr/appel-a-projets-matwin/
MATWIN “Maturation & Accelerating Translation With Industry” is a French accelerator supporting translational innovation in oncology. The programme main objective is to select R&D innovative projects with high transfer potential and therapeutic/ diagnosis application in oncology and to support them in the development and closing of early-stage partnerships to accelerate innovation transfer from bench to the bedside.
This programme is supported by most of the largest companies working in oncology (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and representatives of the French innovation ecosystem (Cancéropôles, TTO, competitive clusters, etc.) Since 2015, MATWIN is a wholly-owned subsidiary from UNICANCER group
MATWIN Call for Applications (open to EU teams) : https://matwin.fr/en/matwins-call-for-application/
MATWIN, Maturation & accelerating translation with industry
MEET2WIN 2021, Convention d'affaires, Programme national, maturation, projets de recherche, académique, oncologie, cancerologie, preuve de concept préclinique, transfert de technologies, industrie pharmaceutique
https://matwin.fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Kamet Ventures Venture Capital and Private Equity Principals | Kamet Ventures Venture Capital and Private Equity Principals | Other 31 May 2024 | | |
 | PariSanté Campus | Other 16 Jul 2024 | | |
 | SATT Nord | Other 16 Jul 2024 | | |
 Finovam Gestion Venture Capital and Private Equity Principals | Finovam Gestion Venture Capital and Private Equity Principals | Other 16 Jul 2024 | | |
 Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Other 16 Jul 2024 | | |
 STATION F Startup accelerator & VC, Software Development | STATION F Startup accelerator & VC, Software Development | Other 16 Jul 2024 | | |
 | SATT Aquitaine Science Transfert | Other 31 May 2024 | | |
 iBionext Startup accelerator & VC, Venture Capital and Private Equity Principals | iBionext Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 6 May 2024 | | |
 Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 6 May 2024 | | |
 | SATT AxLR | Other 9 Apr 2024 | | |